Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trialDirk Schadendorf, Georgina V. Long, John M. Kirkwood et al.|The Lancet Oncology|2019Cited by 56
Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III <i>BRAF</i>-mutant melanoma.Dirk Schadendorf, Georgina V. Long, Vanna Chiarion‐Sileni et al.|Journal of Clinical Oncology|2018Cited by 10